363 related articles for article (PubMed ID: 18357975)
1. Molecular characterization of macbecin as an Hsp90 inhibitor.
Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ
J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975
[TBL] [Abstract][Full Text] [Related]
2. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors.
Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ
J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS
Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ
J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066
[TBL] [Abstract][Full Text] [Related]
5. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
6. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M
Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE
J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999
[TBL] [Abstract][Full Text] [Related]
9. Potent cytotoxic C-11 modified geldanamycin analogues.
Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
[TBL] [Abstract][Full Text] [Related]
10. Potent triazolothione inhibitor of heat-shock protein-90.
Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B
Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743
[TBL] [Abstract][Full Text] [Related]
11. Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.
Crèvecoeur J; Merville MP; Piette J; Gloire G
Biochem Pharmacol; 2008 Jun; 75(11):2183-91. PubMed ID: 18455150
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF
J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664
[TBL] [Abstract][Full Text] [Related]
13. Heat shock protein 90: inhibitors in clinical trials.
Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC
J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425
[No Abstract] [Full Text] [Related]
14. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
[TBL] [Abstract][Full Text] [Related]
15. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y
Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
Shen G; Wang M; Welch TR; Blagg BS
J Org Chem; 2006 Sep; 71(20):7618-31. PubMed ID: 16995666
[TBL] [Abstract][Full Text] [Related]
18. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors.
Li Z; Jia L; Wang J; Wu X; Hao H; Wu Y; Xu H; Wang Z; Shi G; Lu C; Shen Y
Eur J Med Chem; 2014 Nov; 87():346-63. PubMed ID: 25277067
[TBL] [Abstract][Full Text] [Related]
19. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model.
Zapf CW; Bloom JD; McBean JL; Dushin RG; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Levin JI
Bioorg Med Chem Lett; 2011 Jun; 21(12):3627-31. PubMed ID: 21605975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
